[1] Kanki P. J, Hopper J. R, Essex M., The origins of HIV-1 and HTLV-4/HIV-2. Annals of the New York Academy of Sciences. 1987; 511:370-375.

[2] UNAIDS Global Statistics. 2021 [cited May 2022]. Available from: https://www.unaids.org/en/resources/fact-sheet

[3] UNAIDS Press Release Abuja/Geneva 14th March 2019. https:// www.unaids. org/ en/ resou rces/ press centre/ press releaseand state ntarc hive/2019/ march/ 20190 314_ nigeria. Accessed 22 Jan 2020.

[4] National Agency for the Control of AIDS (NACA). Nigeria HIV Prevalence Rate. https:// naca. gov. ng/ Nigeria

[5] Gibbs A., 2010, Understandings of gender and HIV in the South African media. AIDS Care  22 Suppl 2:1620–1628.

[6] Sordo del Castillo L, Ruiz-Pérez I, Olry de Labry Lima A, Biological, psychosocial, therapeutic and quality of life inequalities between HIV positive men and women – a review from a gender perspective. AIDS Rev 2010; 12:113–120.

[7] Mboi, N., 1996, Women and AIDS in south and South-East Asia: the challenge and the response. World Health Stat Q 49:94–105.

[8] World Health Organization, 2013, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization, Geneva.

[9] Federal Ministry of Health, 2016, National Implementation Plan for Scale-Up of Viral Load Testing in Nigeria. Federal Ministry of Health, Nigeria.

[10] Garcia de la Hera M, Ferreros I, del Amo J, Garcia de Olalla P, Perez Hoyos S, Muga R, et al., 2004, Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. Journal of Epidemiology and Community Health. , 58(11):944-950

[11] Kovats S., 2015, Estrogen receptors regulate innate immune cells and signaling pathways. Cellular Immunology, 294(2):63-69.

[12] Overbaugh J, Bangham C, R., 2001 Selection forces and constraints on retroviral sequence variation. Science, 292(5519):1106-1109

[13] Carael M, Marais H, Polsky J, Mendoza A., Is there a gender gap in the HIV response? Evaluating national HIV responses from the United Nations General Assembly Special Session on HIV/AIDS country reports. J Acquir Immune Defic Syndr, 2009; 52 Suppl 2:S111–S118.

[14] Tashima, K. T, Hogan, J. W, Gardner, L. I, Korkontzelou, C, Schoenbaum, E. E, Schuman, P., et al., 2001, A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis, 33:2055–2060.

[15] Carpenter, C. C, Mayer, K. H, Stein, M. D, Leibman BD, Fisher, A, Fiore, T. C., 1991, Human immunodeficiency virus infection in North American women: experience with 200 cases and a review of the literature. Medicine (Baltimore), 60:307–325.

[16] Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, et al., 2005, Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 19(6):577-583.

[17] Minkoff, H. L, Willoughby, A, Mendez, H, Moroso G, Holman S, Goedert J. J, et al., 1990, l. Seriou’s infections during pregnancy among women with advanced human immunodeficiency virus infection. Am J Obstet Gynecol, 162:30-34.

[18] Suba Z., 2020, Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. Journal of Pharmacy & Pharmaceutical Sciences, 23(1):75-85.

[19] Gandhi M, Bacchetti P, Miotti P, Quinn T. C, Veronese F, Greenblatt R. M., 2002, Does patient sex affect human immunodeficiency virus levels? Clinical Infectious Diseases, 35(3):313-322.

[20] Mosha, F., 2021, Gender Differences in Human Immunodeficiency Virus (HIV) Disease Progression and Treatment Outcomes. IntechOpen. doi: 10.5772/intechopen.92898.

[21] Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al., 2011, Sex differences in antiretroviral treatment outcomes among HIV infected adults in an urban Tanzanian setting. AIDS, 25(9):1189-1197.

[22] Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al., 2013, Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: A systematic review and meta-analysis. AIDS, 27(3):417-425.

[23] Onayemi O, Oripelaye M, Afolabi O, and Olanrewaju O., 2018, The effects of gender on clinical and immunological response to antiretroviral therapy among people living with HIV in Ile-Ife, Nigeria. HIV & AIDS Review. International Journal of HIV-Related Problems, 17(4), 278-282. https://doi.org/10.5114/hivar.2018.80260.

[24] Isaac, E. W., Ajani, A., Difa, A. J., Aremu, J. T., Oluwaseun, O. C. and Hassan, M.D., 2021, Viral Suppression in Adult Nigerians in a Regional Antiretroviral Therapy Programme: A Cross Sectional Descriptive Study. World Journal of AIDS, 11, 1-14. https://doi.org/10.4236/wja.2021.111001.

[25] World Health Organization, 2016, Global Report on Early Warning Indicators of HIV Drug Resistance. http://www.who.int/hiv/pub/drugresistance/ewi-hivdr-2016/en/

[26] 90-90-90, An Ambitious Treatment Target to Help End the AIDS Epidemic, UNAIDS, Geneva, Switzerland, 2017, https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf.

[27] Kiweewa, F, Esber, A, Musingye, E, Reed D, Crowell T. A, Cham F, et al., 2019, HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS One,14:1–16. https:// doi. org/ 10. 1371/ journ al. pone. 02113 44.

[28] Tchouwa, G.T., Eymard-Duvernay, S., Cournil, A., Lamare, N., Serrano, L., Butel, C., et al., 2018, Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. Clinical Medicine, 1, 21-27. https://doi.org/10.1016/j.eclinm.2018.06.005.

[29] Ofori-Attah P, Ameke L. S, Obirikorang, C, Orish, V. N, Kpene, G. E, Agboli, E, et al, 2020, Viral suppression and its associated factors in HIV patients on highly active antiretroviral therapy (HAART): a retrospective study in the Ho Municipality, Ghana. AIDS Res Treat, 1–7.

[30] Desta, A. A, Tewolde, W. W, Futwi, N, Gebrecherkos, T. G, Goyitom, G. G, Asfawosen, A. B, et al., 2020, HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. BMC Infect Dis., 20:1–10.

[31] Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, et al., 2020, Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. J Antimicrob Chemother, 75(5):1280–9. https:// doi.org/ 10. 1093/ jac/dkz561

[32] Cornell, M., Schomaker, M., Garone, D. B., Giddy, J., Hoffmann, C. J., Lessells, R., et al., 2012, Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Medicine, 9, e1001304. https://doi.org/10.1371/journal.pmed.1001304.

[33]  De Beaudrap, P., Thiam, M., Diouf, A., Toure-Kane, C., Ngom-Gueye, N.F., Vidal, N., et al., 2013, Risk of Virological Failure and Drug Resistance during First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal: Results from the ANRS 1215 Cohort. Journal of Acquired Immune Deficiency Syndromes, 62, 381-387. https://doi.org/10.1097/QAI.0b013e31827a2a7a

[34]  Datay, M. I., Boulle, A., Mant, D. and Yudkin, P., 2010, Associations with Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes, 54, 489-495. https://doi.org/10.1097/QAI.0b013e3181d91788.

[35]  Abioye, A. I., Soipe, A. I., Salako, A. A., Odesanya, M. O., Okuneye, T. A., Abioye, A. I., et al., 2015, Are There Differences in Disease Progression and Mortality among Male and Female HIV Patients on Antiretroviral Therapy? A Meta-Analysis of Observational Cohorts. AIDS Care, 27, 1468-1486. https://doi.org/10.1080/09540121.2015.1114994

[36]  Beckham, S. W., Beyrer, C., Luckow, P., Doherty, M., Negussie, E. K. and Baral, S. D., 2016, Marked Sex Differences in All-Cause Mortality on Antiretroviral Therapy in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Journal of the International AIDS Society, 19, Article ID: 21106. https://doi.org/10.7448/IAS.19.1.21106

[37]  Sunkanmi F, Paul Y, Peter D, Nsikan A, Joseph J, Opada E, et al. Factors influencing viral load non-suppression among people living with HIV (PLHIV) in Borno State, Nigeria: a case of Umaru Shehu Ultra-Modern Hospital. J Adv Med Res. 2020; 32:98–105.